Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$84.93 USD

84.93
2,385,980

+0.61 (0.72%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q4 Earnings

Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2021 on the fourth-quarter earrings call.

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

Is (MRNA) Outperforming Other Medical Stocks This Year?

Pfizer (PFE), BioNTech Test COVID-19 Vaccine in Pregnant Women

Pfizer (PFE) and BioNTech begin dosing in a mid-to-late-stage study on their COVID-19 vaccine in healthy pregnant women.

Stock Market News for Feb 19, 2021

Benchmarks closed in the red on Thursday as unexpected rise in weekly initial jobless claims overshadowed promising corporate earnings results and declining number of coronavirus cases.

Tempur Sealy, Beyond Meat, Moderna, AstraZeneca and Merck highlighted as Zacks Bull and Bear of the Day

Tempur Sealy, Beyond Meat, Moderna, AstraZeneca and Merck highlighted as Zacks Bull and Bear of the Day

Kinjel Shah headshot

4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

Smart Beta ETF report for FAD

Moderna (MRNA) Expected to Beat Earnings Estimates: Should You Buy?

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat in Store for Moderna (MRNA) This Earnings Season?

Investor focus is likely to be on any update on the timeline of filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the fourth-quarter earrings call.

Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to EU

Pfizer (PFE)/BioNTech (BNTX) win a deal for 200 million more doses of its COVID-19 vaccine in Europe.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

Moderna (MRNA) closed the most recent trading day at $176.76, moving -0.99% from the previous trading session.

Kevin Cook headshot

Hedge Fund Diaries: Who Was Buying Your Stocks?

SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.

J&J (JNJ) Seeks Conditional Nod for COVID-19 Vaccine in EU

J&J's (JNJ) COVID-19 vaccine, if approved, will be the only COVID-19 vaccine to be approved for single administration.

What's in the Cards for Arcturus (ARCT) This Earnings Season?

Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2020 results.

What's in the Cards for Intellia (NTLA) This Earnings Season?

Intellia Therapeutics (NTLA) is likely to discuss the progress of its pipeline candidate on its fourth-quarter earnings call.

What's in the Cards for Sarepta (SRPT) This Earnings Season?

Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.

Pfizer (PFE) Gets FDA Nod for New Indication of Immunoglobulin

Pfizer's (PFE) Panzyga gets FDA approval to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disease.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $179.34, marking a -0.1% move from the previous day.

Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?

Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q4.

Exact Sciences (EXAS) to Report Q4 Earnings: What's in the Cards?

Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.

Are You Looking for a Top Momentum Pick? Why Moderna (MRNA) is a Great Choice

Does Moderna (MRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?

Investors will focus on pipeline and guidance updates when Exelixis (EXEL) reports fourth-quarter 2020 results.

J&J (JNJ) Seeks Emergency Approval for Coronavirus Vaccine

Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking emergency use approval for its single-shot coronavirus vaccine.

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.